Although not all patients with urothelial neoplasia can benefit from MTAP IHC, this approach appears to be highly useful in subsequent biopsies or cytological samples of patients with a previously diagnosed MTAP‐deficient urothelial neoplasm. Here, MTAP is linked to urothelial neoplasm.